Showing results (221-230 of 259) with videos related to
Sort By:
Pageof 26
European Journal of Cancer (Oxford, England : 1990)|July 10, 2024
Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancerEnriqueta Felip, Giulio Metro, Ross A Soo, et al.The Lancet. Oncology|April 17, 2016
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trialKeunchil Park, Eng-Huat Tan, Ken O'Byrne, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2016
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung CancerShirish M Gadgeel, Alice T Shaw, Ramaswamy Govindan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2024
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722Tony Mok, Kazuhiko Nakagawa, Keunchil Park, et al.The New England Journal of Medicine|June 3, 2024
Osimertinib after Chemoradiotherapy in Stage III <i>EGFR</i>-Mutated NSCLCShun Lu, Terufumi Kato, Xiaorong Dong, et al.Cancer Research|April 20, 2018
Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK InhibitorsMi Ran Yun, Sun Min Lim, Seon-Kyu Kim, et al.Lung Cancer (Amsterdam, Netherlands)|April 29, 2025
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subsetByoung Chul Cho, Hidetoshi Hayashi, Jong-Seok Lee, et al.Nature Medicine|July 10, 2023
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim resultsMartin Gutierrez, Wei-Sen Lam, Matthew D Hellmann, et al.Cancer Discovery|April 11, 2022
Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsMengzhao Wang, James Chih-Hsin Yang, Paul L Mitchell, et al.Clinical Lung Cancer|September 23, 2022
Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic ConsiderationsMyung-Ju Ahn, Marvin Jonne L Mendoza, Nick Pavlakis, et al.Pageof 26